AbbVie to Acquire Antibody-drug Conjugate Specialist ImmunoGen
AbbVie is set to acquire ImmunoGen in a $10.1B deal which encompasses ImmunoGen’s first-in-class antibody-drug conjugate (ADC) cancer treatment ELAHERE®
Read moreAbbVie is set to acquire ImmunoGen in a $10.1B deal which encompasses ImmunoGen’s first-in-class antibody-drug conjugate (ADC) cancer treatment ELAHERE®
Read moreBoehringer Ingelheim has confirmed the acquisition of T3 Pharmaceuticals AG, a Swiss clinical-stage biotech company thereby expanding its immuno-oncology portfolio.
Read moreVANFLYTA® (quizartinib) is now the first FLT3 inhibitor approved in the European Union (EU) specifically for the treatment of patients
Read moreElly Lilly announced plans to acquire POINT Biopharma, with the strategic move set to boost Lilly’s oncology capabilities with next-generation
Read moreOrano Med, a clinical-stage biotechnology company that develops the next generation of targeted therapies against cancer using the unique properties
Read moreEisai Co., Ltd. revealed that it has partnered with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. to develop BB-1701, an antibody-drug conjugate
Read moreJanssen has received its first worldwide approval for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) as EC Authorized treatment
Read moreCompugen will present new research at AACR 2023 that allows for the accurate detection and study of novel target PVRIG.
Read morePharma giant Pfizer and American biotech company Seagen officially announced on Monday that they have reached a conditional merger agreement
Read moreChicago Headquartered Tempus, pioneering AI-enabled precision medicine, has entered a third strategic collaboration with pharma giant Pfizer, aiming to gather
Read more